← Patent-cliff monitor small molecule SUNLENCA LENACAPAVIR SODIUM
Loss of exclusivity August 2041 latest FDA-listed patent expiry
Drug detail Brand name SUNLENCA Active ingredient LENACAPAVIR SODIUM Strength EQ 463.5MG BASE/1.5ML (EQ 309MG BASE/ML) Dosage form SOLUTION Route SUBCUTANEOUS Modality Small molecule FDA approval December 2022 Marketing status RX
Listed patents Patent Expires Type 11944611 August 2041 use U-3507 12594267 July 2039 product 11267799 August 2038 substance 10654827 August 2037 use U-3507 10071985 August 2037 substance, product 9951043 February 2034 substance, product
Regulatory exclusivity Code Expires NCE December 2027
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.